rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SOPH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      SOPHiA: 3 Key Takeaways for Long-Term Investors
      Nov 16Yahoo FinanceSOPH
      SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceSOPH
      SOPHiA GENETICS Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceSOPH
      Earnings call transcript: SOPHiA GENETICS misses Q3 2026 EPS, shares slip premarket
      Nov 3Investing.comSOPH
      Sophia Genetics Q3 2026 Earnings Call Transcript
      Nov 3BenzingaSOPH
      Sophia Genetics earnings missed by $0.06, revenue topped estimates
      Nov 3Investing.comSOPH
      SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates
      Nov 3Yahoo FinanceSOPH
      SOPHiA GENETICS Reports Third Quarter 2026 Results
      Nov 3Yahoo FinanceSOPH
      SOPHiA GENETICS to Announce Financial Results for Third Quarter 2026 on November 3, 2026

      SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2026 before U.S. markets open on Tuesday, November 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET.

      Oct 20Yahoo FinanceSOPH
      Amid the Biotech Madness, I Spotted an Opening in a Promising Small-Cap

      Hedge funds dumped genomics plays like this one last week … but it was just as it announced a new AstraZeneca-linked deal.

      Oct 12TheStreetSOPH
      Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
      Oct 8Seeking AlphaAZNMYGNSOPH
      Myriad Genetics, SOPHiA partner on prostate cancer biomarker
      Oct 8Investing.comMYGNSOPH
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Sophia Genetics Sa (SOPH-Q) from The Globe and Mail including charting and trades.

      Sep 29The Globe and MailSOPH
      SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?

      SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

      Sep 18Yahoo FinanceSOPH
      SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization Inflect
      Sep 16Seeking AlphaSOPH
      SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance Raise

      SOPHiA GENETICS is back in focus as analysts reset their central price views, with fair value moving from US$9.00 to US$9.75. Recent research linking the company’s role in data driven oncology and rare disease diagnostics with Q2 results and higher guidance has supported price targets in a US$9 to US$12 range, while still flagging execution and valuation risk. Read on to see how these shifting targets feed into the broader SOPHiA GENETICS story and how you can track the narrative from...

      Sep 4Yahoo FinanceSOPH

      This is the newest page. Registered accounts read further back.